Gut health firm Viome has announced a partnership with Microsoft to build an AI infrastructure for the human microbiome – a move that could mark the next frontier in personalised health.
At first glance, it sounds like a routine tech deal. In reality, it’s a major step toward programmable biology.
Inside the partnership
Viome’s goal is to use RNA sequencing to map and influence gene expression in the gut – essentially translating what your microbiome is doing in real time. The collaboration gives Viome access to Microsoft’s specialised AI infrastructure, unlocking new levels of scale, speed, and computational intelligence.
So far, Viome has collected over one million gut samples and analysed more than 10 quadrillion biological data points. Unlike DNA testing, which shows genetic potential, RNA reveals what’s actively happening inside the body – from inflammation spikes to bacterial imbalances that influence metabolism and ageing.
Why it matters
Microsoft’s involvement signals Big Tech’s growing focus on biological data.
The microbiome affects everything from digestion and immunity to cognition, inflammation, and longevity. Disruptions in gut balance are now associated with conditions including diabetes, obesity, IBS, and depression.
Alongside testing, microbiome therapy is quickly evolving. The most striking example is FMT – faecal microbiota transplant – a treatment that transfers healthy gut bacteria from one person to another to restore microbial balance.
It may sound unappealing, but the science is compelling. A 2013 New England Journal of Medicine study found FMT cured 94% of C. difficile infections, compared with 31% for antibiotics.
Not everyone is convinced. “FMT should only be used when medically indicated to treat a serious condition, not speculatively or prophylactically,” says Robert Parsons, a forensic toxicologist. “Without exceedingly stringent quality controls there are very serious potential risks. It should not be taken lightly and should require a valid prescription from a medical doctor.”
Others are more optimistic. “The approach has tremendous potential in a wide range of indications, but the [negative] comments reflect the obvious reluctance that some may feel,” says Dr David Rhodes, a biologics product developer. “I can only assume that these individuals are not suffering from one of the diseases for which there is a strong database to demonstrate efficacy. I’d like to think that anyone facing that situation would appreciate the potential and might benefit from the option.
“We are still in the early stages of developing microbiome based treatments. FMT is remarkably effective for indications like C. diff. [In my view] there’s great potential for microbiome-based treatments for everything from autism to cancer, but public acceptance – even when we’ve evolved beyond FMT and have mountains of supporting data – may be a challenge.”
After years of limited attention, Big Pharma has taken note. The FDA has now approved two microbiome therapies: Rebyota (from Ferring Pharmaceuticals) and Vowst (from Seres Therapeutics). More developments are already emerging, including precision-engineered microbial blends, freeze-dried capsules, and AI-driven personalisation tools.
The bigger picture
The Microsoft x Viome alliance is the first serious attempt to scale microbiome diagnostics using Big Tech AI. But there’s still a missing piece: a feedback loop that helps people act on their data. “This is a fascinating development that highlights the dynamic intersection of biotechnology and AI,” says Jonas Paulavičius, CTO at DieDai Health. “Scaling microbiome-based diagnostics through platforms like Viome, with Microsoft’s backing, underscores an impressive commitment to innovation in personalized health. It’s crucial, though, to ensure these tools not only collect extensive data but also actively enhance health outcomes by closing feedback loops. Otherwise, they risk being sophisticated data collectors without substantive impact on individual well-being. The potential of AI in transforming gut health is immense, but its success will depend on its integration into actionable, personalised health interventions.”
In the future of personalised health, the winners won’t be the brands that collect the most information — they’ll be the ones that make change easier.
AI plus RNA could mark the start of programmable gut health.
If Viome can close the loop and prove the model, it could lay the foundations for a new biological operating system.
If not, someone else will.
